Jump Financial LLC Has $865,000 Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Jump Financial LLC raised its position in Replimune Group, Inc. (NASDAQ:REPL) by 95.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 71,443 shares of the company’s stock after buying an additional 34,907 shares during the quarter. Jump Financial LLC’s holdings in Replimune Group were worth $865,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Replimune Group by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company’s stock worth $43,546,000 after acquiring an additional 129,601 shares in the last quarter. State Street Corp boosted its holdings in shares of Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Replimune Group by 352.5% during the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company’s stock worth $13,282,000 after buying an additional 854,346 shares during the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in Replimune Group in the fourth quarter valued at about $7,399,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Stock Performance

NASDAQ REPL opened at $8.77 on Tuesday. The company has a market capitalization of $675.42 million, a price-to-earnings ratio of -2.86 and a beta of 1.26. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The stock has a fifty day simple moving average of $10.65 and a 200 day simple moving average of $11.73. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Sell-side analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on REPL shares. BMO Capital Markets raised their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Replimune Group has an average rating of “Buy” and an average price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.